title: HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
abstract: BACKGROUND
  Anti-CADM-140 antibody (anti-CADM-140), also referred to as anti-melanoma differentiation-associated gene 5 (MDA5) antibody, is a myositis-specific antibody identified in the sera of patients with clinically amyopathic dermatomyositis (C-ADM) and is associated with a worse prognosis in dermatomyositis-associated interstitial lung disease (DM-ILD). We sought to determine high-resolution computed tomography (HRCT) features of DM-ILD with anti-CADM-140.
  
  
  METHODS
  Twenty-five patients newly diagnosed with DM-ILD at Kyoto University Hospital between 2005 and 2009 were retrospectively reviewed. Serum anti-CADM-140 was measured in all patients at their first visit. Chest HRCT images taken prior to treatment were classified based on the dominant findings and their distribution, and compared between patients with and without the antibody.
  
  
  RESULTS
  Of 25 DM-ILD patients, 12 were positive and 13 were negative for anti-CADM-140. HRCT patterns differed significantly between anti-CADM-140-positive and negative patients (P = 0.002). Lower consolidation or ground-glass attenuation (GGA) pattern (50.0%) and random GGA pattern (33.3%) were the predominant patterns in anti-CADM-140-positive cases, while lower reticulation pattern (69.2%) was frequently seen in anti-CADM-140-negative cases. Anti-CADM-140-positive cases were also significantly characterized by the absence of intralobular reticular opacities (0% in anti-CADM-140 (+) vs. 84.6% in anti-CADM-140 (-), P < 0.0001).
  
  
  CONCLUSIONS
  Anti-CADM-140-positive DM-ILD was characterized by lower consolidation or GGA pattern, random GGA pattern, and the absence of intralobular reticular opacities.
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Kiminobu
authors.initials: K
authors.lastname: Tanizawa
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Handa
authors.forename: Ran
authors.initials: R
authors.lastname: Nakashima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubo
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hosono
authors.forename: Kizuku
authors.initials: K
authors.lastname: Watanabe
authors.forename: Kensaku
authors.initials: K
authors.lastname: Aihara
authors.forename: Toru
authors.initials: T
authors.lastname: Oga
authors.forename: Kazuo
authors.initials: K
authors.lastname: Chin
authors.forename: Sonoko
authors.initials: S
authors.lastname: Nagai
authors.forename: Tsuneyo
authors.initials: T
authors.lastname: Mimori
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mishima
mesh_terms: D001323:Autoantibodies / Q000276:immunology; D003882:Dermatomyositis / Q000150:complications / Q000000981:diagnostic imaging* / Q000276:immunology; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D017563:Lung Diseases, Interstitial / Q000000981:diagnostic imaging* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000276:immunology*; D011379:Prognosis; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D001323:Autoantibodies; C501597:CADM-140 peptide, human; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides